1. Home
  2. PIII vs GBIO Comparison

PIII vs GBIO Comparison

Compare PIII & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PIII
  • GBIO
  • Stock Information
  • Founded
  • PIII 2015
  • GBIO 2016
  • Country
  • PIII United States
  • GBIO United States
  • Employees
  • PIII N/A
  • GBIO N/A
  • Industry
  • PIII Medical/Nursing Services
  • GBIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • PIII Health Care
  • GBIO Health Care
  • Exchange
  • PIII Nasdaq
  • GBIO Nasdaq
  • Market Cap
  • PIII 28.6M
  • GBIO 29.5M
  • IPO Year
  • PIII N/A
  • GBIO 2020
  • Fundamental
  • Price
  • PIII $8.38
  • GBIO $5.95
  • Analyst Decision
  • PIII Strong Buy
  • GBIO Buy
  • Analyst Count
  • PIII 3
  • GBIO 4
  • Target Price
  • PIII $17.50
  • GBIO $10.67
  • AVG Volume (30 Days)
  • PIII 7.0K
  • GBIO 75.1K
  • Earning Date
  • PIII 11-11-2025
  • GBIO 11-05-2025
  • Dividend Yield
  • PIII N/A
  • GBIO N/A
  • EPS Growth
  • PIII N/A
  • GBIO N/A
  • EPS
  • PIII N/A
  • GBIO N/A
  • Revenue
  • PIII $1,461,823,000.00
  • GBIO $21,230,000.00
  • Revenue This Year
  • PIII N/A
  • GBIO N/A
  • Revenue Next Year
  • PIII $9.46
  • GBIO N/A
  • P/E Ratio
  • PIII N/A
  • GBIO N/A
  • Revenue Growth
  • PIII 4.20
  • GBIO 61.15
  • 52 Week Low
  • PIII $5.80
  • GBIO $3.00
  • 52 Week High
  • PIII $26.99
  • GBIO $29.10
  • Technical
  • Relative Strength Index (RSI)
  • PIII 59.01
  • GBIO 52.30
  • Support Level
  • PIII $8.46
  • GBIO N/A
  • Resistance Level
  • PIII $8.90
  • GBIO $6.25
  • Average True Range (ATR)
  • PIII 0.32
  • GBIO 0.30
  • MACD
  • PIII -0.02
  • GBIO -0.30
  • Stochastic Oscillator
  • PIII 49.07
  • GBIO 91.82

About PIII P3 Health Partners Inc.

P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Share on Social Networks: